Bsc Biology, University of Crete (1992) Medical Degree, University of Crete (1997) Specialization in Hematology at the Hematology Department of the University hospital of Heraklion under the supervision of Prof. HA Papadaki (2000-2006) Training in Labor fόr Leukozytenimmunologie Deutsches Rotes Kreuz Blood Service West, Hagen, Germany. Topic: Granulocyte serology-Detection of anti-neutrophil antibodies Supervisor: Professor: J. Bux (2005) PhD Thesis in Hematology, University of Crete, School of Medicine (2006)

Education/Training:

Areas of research interests:

• Investigation of the pathogenesis of Chronic Idiopathic Neutropenia
• Investigation of the expression of the immunoregulatory molecule CD200 by cultured Bone Marrow Mesenchymal Stem Cells and study of its role in osteoclastogenesis
• Study of the quantitative, functional, cytogenetic and immunoregulatory properties of Bone Marrow Mesenchymal Stem Cells (BM-MSCs) in patients with benign and neoplastic hematological disorders
• Study of the qualitative and quantitative characteristics of ex-vivo expanded Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs).
• Study of factors/pathways implicated in stemness and/or differentiation of BM- and WJ-MSCs
• Investigation of the osteoinductive potential of BM-and WJ-MSCS immobilized on novel implantable biomaterials
• Investigation of circulating endothelial progenitor cells and BM MSCs in patients with arterial hypertension and ventricular hypertrophy, as well as in younger patients with type I diabetes mellitus

Selected publications in peer-reviewed journals:

DAMIANAKI A, STAGAKIS E, MAVROUDI I, SPANOUDAKIS M, KOUTALA H, PAPADOGIANNIS F, KANELLOU P, PONTIKOGLOU C, PAPADAKI HA. Minor populations of paroxysmal nocturnal haemoglobinuria type cells in patients with chronic idiopathic neutropenia. Eur J Haematol. 2016 Apr 28. [Epub ahead of print]

KOUVIDI E, STRATIGI A, BATSALI A, MAVROUDI I, MASTRODEMOU S, XIMERI M, PAPADAKI HA .PONTIKOGLOU CG. Cytogenetic evaluation of mesenchymal stem/stromal cells from patients with myelodysplastic syndromes at different time-points during ex vivo expansion. Leuk Res. 2016;43:24- 32.

PONTIKOGLOU C, LANGONNE A, BA MA, VARIN A, ROSSET P, CHARBORD P, SENSEBE L, DESCHASEAUX F. CD200 expression in human cultured bone marrow mesenchymal stem cells is induced by pro-
osteogenic and pro-inflammatory cues.J Cell Mol Med. 2016;20:655-65

KALYVA A, MARKETOU ME, PARTHENAKIS FI, PONTIKOGLOU C, KONTARAKI JE, MARAGKOUDAKIS S, PETOUSIS S, CHLOUVERAKIS G, PAPADAKI HA, VARDAS P Endothelial progenitor cells as markers of severity in hypertrophic cardiomyopathy. Eur J Heart Fail. 2016 Feb;18(2):179-84.

KYRITSI EM, YIAKOUMIS X, PANGALIS GA, PONTIKOGLOU C, PYROVOLAKI K, KALPADAKIS C, MAVROUDI I, KOUTALA H, MASTRODEMOU S, VASSILAKOPOULOS TP, VAIOPOULOS G, DIAMANTI- KANDARAKIS E, PAPADAKI HA, ANGELOPOULOU MK. High Frequency of Thyroid Disorders in Patients Presenting With Neutropenia to an Outpatient Hematology Clinic STROBE-Compliant Article. Medicine (Baltimore). 2015 Jun;94(23):e886.

MARKETOU ME, PARTHENAKIS FI, KALYVA A, PONTIKOGLOU C, MARAGKOUDAKIS S, KONTARAKI JE, ZACHARIS EA, PATRIANAKOS A, CHLOUVERAKIS G, PAPADAKI HA, VARDAS PE.                                                                                     Circulating

mesenchymal stem cells in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2015; 24:149-53

CHATZINIKOLAIDOU M, REKSTYTE S, DANILEVICIUS P, PONTIKOGLOU C, PAPADAKI H, FARSARI M, VAMVAKAKI M. Adhesion anf growth of human bone marrow mesenchymal stem cells on precise geometry 3D organic-inorganic composite scaffolds for bone repair. Mater Sci Eng C Mater Biol Appl. 2015;48:301-9

MARKETOU ME, PARTHENAKIS FI, KALYVA A, PONTIKOGLOU C, MARAGKOUDAKIS S, KONTARAKI JE, ZACHARIS EA, CHLOUVERAKIS G, PATRIANAKOS A, PAPADAKI HA, VARDAS PE. Increased mobilization of mesenchymal stem cells in patients with essential hypertension: the effect of left ventricular hypertrophy. J Clin Hypertens 2014;16:883-8

MARKETOU ME, KALYVA A, PARTHENAKIS FI, PONTIKOGLOU C, MARAGKOUDAKIS S, KONTARAKI JE, CHLOUVERAKIS G, ZACHARIS EA, PATRIANAKOS A, PAPADAKI HA, VARDAS PE. CirculatingEndothelial Progenitor Cells in Hypertensive Patients With Increased Arterial Stiffness. J Clin Hypertens (Greenwich). 2014; 16:295-300

PAVLAKI K, PONTIKOGLOU C, DEMETRIADOU A, BATSALI AK, DAMIANAKI A, S IMANTIRAKIS                    E,

KONTAKIS M, GALANOPOULOS A, KOTSIANIDIS I, KASTRINAKI M-C, PAPADAKI H. Impaired proliferative potential of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes is associated with abnormal Wnt signaling pathway Stem Cells Dev 2014;23:1568-81 KASTRINAKI MC, PAVLAKI K, BATSALI A, KOUVIDI E, MAVROUDI E, PONTIKOGLOU C, PAPADAKI H. Mesenchymal Stem Cells in Immune-Mediated Bone Marrow Failure Syndromes Clin Dev Immunol 2013:265608

STALIKA E, PAPALEXANDRI A, ISKAS M, STAVROYIANNI N, KANELLIS G, KOTTA K, PONTIKOGLOU C, SIORENTA A, ANAGNOSTOPOULOS A, PAPADAKI H, PAPADAKI T, STAMATOPOULOS K. Familial CD3+ TLarge Granular Lymphocyte Leukemia: Evidence that Genetic Predisposition and Antigen SelectionPromote Clonal Cytotoxic T-Cell Responses. Leuk Lymphoma 2014; 55:1781-7

CHATZINIKOLAIDOU M, KALIVA M, BATSALI A, PONTIKOGLOU C, VAMVAKAKI M. Wharton's jelly mesenchymal stem cell response on chitosan-grafted-poly^-caprolactone) for myoc- ardium tissue engineering, Current Pharmaceutical Design 2014;20:2030-9

VARIN A, PONTIKOGLOU C, LABAT E, ROSSET P, CHARBORD P, DESCHASEAUX F, SENSEBE L. CD200R/CD200 inhibits osteoclastogenesis: New mechanism of osteoclast control by mesenchymal stem cells. Plos ONE 2013 5;8:e72831

PONTIKOGLOU C, KASTRINAKI MC, KLAUS M, KALPADAKIS C, KATONIS P, ALPANTAKI K, PANGALIS GA, PAPADAKI HA. Study of the quantitative, functional, cytogenetic and immuno- regulatoryproperties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocyticleukemia. Stem Cells Dev. 2013;22:1329-41

BATSALI AK, KASTRINAKI MC, PAPADAKI HA, PONTIKOGLOU C. Mesenchymal stem cells derivedfrom Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther. 2013;8:144-55

GEMETZI C, MAVROUDI I, KOUTALA H, VELEGRAKI M, CHOULAKI C, DAMIANAKI A, PONTIKOGLOU C, PAPADAKI HA. Lymphopenia in patients with chronic idiopathic neutropenia is associated withdecreased number of T-lymphocytes containing T-cell receptor excision circles. Eur J Haematol. 2012;88:210-23

PONTIKOGLOU C, DESCHASEAUX F, SENSEBE L, PAPADAKI HA. Bone Marrow Mesenchymal Stem Cells: Biological Properties and Their Role in Hematopoiesis and Hematopoietic Stem Cell Transplantation. Stem Cell Rev Rep. 2011;7:569-89

STAVROULAKI E, KASTRINAKI MC, PONTIKOGLOU C, ELIOPOULOS D, DAMIANAKI A, MAVROUDI I, PYROVOLAKI K, KATONIS P, PAPADAKI HA. Mesenchymal Stem Cells Contribute to the Abnormal Bone Marrow Microenvironment in Patients with Chronic Idiopathic Neutropenia by Overproduction of Transforming Growth Factor-β!. Stem Cells Dev. 2011; 20:1309-1318

KASTRINAKI MC, PONTIKOGLOU C, KLAUS M, STAVROULAKI E, PAVLAKI K, PAPADAKI HA. Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes. Curr Stem Cell Res Ther. 2011;6:122-130

MAVROUDI I, PYROVOLAKI K, PAVLAKI K, KOZANA A, PSYLLAKI M, KALPADAKIS C, PONTIKOGLOU C, PAPADAKI HA. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res. 2011; 35:323-328 KLAUS M, STAVROULAKI E, KASTRINAKI MC, FRAGIOUDAKI P, GIANNIKOU K, PSYLLAKI M, PONTIKOGLOU CG, TSOUKATOU D, MAMALAKI C, PAPADAKI HA. Reserves, functional, immunoregulatory and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev. 2010; 19:1043-54

PONTIKOGLOU C, PAPADAKI HA. Idiosyncratic drug-induced agranulocytosis: the paradigm ofdeferiprone. Hemoglobin. 2010; 34:291-30

DESCHASEAUX F, PONTIKOGLOU C, SENSEBE L. Bone regeneration: the stem/progenitor cells point of view. J Cell Mol Med. 2010; 14:103-15

XIMERI M, GALANOPOULOS A, KLAUS M, PARCHARIDOU A, GIANNIKOU K, PSYLLAKI M, SYMEONIDIS A, PAPPA V, KARTASIS Z, LIAPI D, HATZIMICHAEL E, KOKORIS S, KORKOLOPOULOU P, SAMBANI C, PONTIKOGLOU C, PAPADAKI HA; on behalf of the Hellenic MDS Study Group. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndromes associated with chromosome 5q deletion. Haematologica 2010; 95:406-14

ELIOPOULOS DG, MAVROUDI I, PONTIKOGLOU C, XIMERI M, STAVROULAKI E, PYROVOLAKI K, VELEGRAKI M, PAPADAKI HA. The -509C/T polymorphism of transforming growth factor-βΐis associated with increased risk for development of chronic idiopathic neutropenia. Eur J Haematol 2009; 83:535-40

DELORME Β, RINGE J, PONTIKOGLOU C, GAILLARD J, LANGONNE A, SENSEBE L, NOEL D, JORGENSEN C, HAUPL T, CHARBORD P. Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity Stem Cells 2009; 27:1142-51

PAPADAKI HA AND PONTIKOGLOU C Pathophysiologic mechanisms, clinical features and treatment of idiopathic neutropenia. Expert Rev. Hematol. 2008; 1:217-229

PONTIKOGLOU C, PAPADAKI HA. Human Bone Marrow Mesenchymal Stem Cells: Characteristics and therapeutic applications. Haema 2008; 11:64-74

PONTIKOGLOU C, DELORME B, CHARBORD P. Human bone marrow native mesenchymal stem cells. Regen Med 2008; 3:731-741

STAMATOPOULOS K, PAPADAKI T, PONTIKOGLOU C, ATHANASIADOU I, STAVROYIANNI N, BUX J,BATSIS I, PYROVOLAKI K, PATERAKIS G, ANAGNOSTOU D, ANAGNOSTOPOULOS A, PAPADAKI HA. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab- treated lymphoma patients with late-onset neutropenia. Leukemia. 2008; 22:1446-9 KOUMAKI V, DAMIANAKI A, XIMERI M, PONTIKOGLOU C, AXIOTI F, SPANOUDAKIS M, ELIOPOULOSGD, PAPADAKI HA. Pro-inflammatory bone marrow milieu in patients with chronic idiopathic neutropenia is associated with impaired local production of interleukin-10. Br J Haematol. 2006; 135:570-3

PONTIKOGLOU C, LIAPAKIS G, PYROVOLAKI A, PAPADAKIS M, BUX J, ELIOPOULOS GD, PAPADAKI HA. Evidence for downregulation of Erythropoietin receptor in bone marrow erythroid cells of patients with chronic idiopathic neutropenia. Exp Hematol2006; 34:1312-22

BOULA A, VOULGARELIS M, GIANNOULI S, KATRINAKIS G, PSYLLAKI M, PONTIKOGLOU C, MARKIDOUF, ELIOPOULOS GD, PAPADAKI HA. Effect of cA2 Anti-Tumor Necrosis Factor-{alpha} Antibody Therapy on Hematopoiesis of Patients with Myelodysplastic Syndromes. Clin Cancer Res. 2006; 12:3099-108 PAPADAKI HA, DAMIANAKI A, PONTIKOGLOU C, PYROVOLAKI K, ELIOPOULOS DG, STAVROULAKI E,ELIOPOULOS GD. Increased levels of soluble flt-3 ligand in serum and long-term bone marrow culture supernatants in patients with chronic idiopathic neutropenia. Br J Haematol. 2006; 132:637-9 PAPADAKI HA, PONTIKOGLOU C, ELIOPOULOS DG, PYROVOLAKI K, SPYRIDAKI R, ELIOPOULOS GD. Helicobacter pylori infection is probably the cause of chronic idiopathic neutropenia (CIN)-associated splenomegaly. Am J Hematol. 2006; 81:142-4

PAPADAKI HA, PONTIKOGLOU C, STAVROULAKI E, ELIOPOULOS DG, MAVROUDI I, SPANOUDAKIS M,ELIOPOULOS GD. Soluble c-kit ligand production by bone marrow stromal cells is independent of the degree of neutropenia in patients with chronic idiopathic neutropenia. Ann Hematol. 2006; 85:170-3 PAPADAKI HA, TSAGOURNISAKIS M, MASTORODEMOS V, PONTIKOGLOU C, DAMIANAKI A,PYROVOLAKI K, STAMATOPOULOS K, FASSAS A, PLAITAKIS A, ELIOPOULOS GD. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Bone Marrow Transplant. 2005; 36:1053­63

PAPADAKI HA, PONTIKOGLOU C, STAVROULAKI E, MINADAKIS G, ELIOPOULOS DA, PYROVOLAKI K,SKORDILIS P, ELIOPOULOS GD. High prevalence of Helicobacter pylori infection and monoclonal gammopathy of undetermined significance in patients with chronic idiopathic neutropenia. Ann Hematol. 2005; 84:317-20

PAPADAKI HA, TSATSANIS C, CHRISTOFORIDOU A, MALLIARAKI N, PSYLLAKI M, PONTIKOGLOU C,MILIAKI M, MARGIORIS AN, ELIOPOULOS GD. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/ osteoporosis. J Bone Miner Metab. 2004; 22:577-87